Cargando…

Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center

BACKGROUND: Large randomized clinical trials of patients with type 2 diabetes mellitus (T2DM) and at high risk for cardiovascular disease revealed that sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduced renal events. However, the trials included small numbers of patients with mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugiyama, Seigo, Jinnouchi, Hideaki, Yoshida, Akira, Hieshima, Kunio, Kurinami, Noboru, Jinnouchi, Katsunori, Tanaka, Motoko, Suzuki, Tomoko, Miyamoto, Fumio, Kajiwara, Keizo, Jinnouchi, Tomio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436561/ https://www.ncbi.nlm.nih.gov/pubmed/30937117 http://dx.doi.org/10.14740/jocmr3761

Ejemplares similares

The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018)

Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018)

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
por: Sugiyama, Seigo, et al.
Publicado: (2018)

Initial Acute Decline in Estimated Glomerular Filtration Rate After Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Chronic Kidney Disease
por: Sugiyama, Seigo, et al.
Publicado: (2020)

Smoking Cessation Ameliorates Microalbuminuria With Reduction of Blood Pressure and Pulse Rate in Patients With Already Diagnosed Diabetes Mellitus
por: Hieshima, Kunio, et al.
Publicado: (2018)

A pilot study of ezetimibe vs. atorvastatin for improving peripheral microvascular endothelial function in stable patients with type 2 diabetes mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2015)

Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus
por: Kurinami, Noboru, et al.
Publicado: (2017)

Body Muscle-to-Fat Ratio, Rather Than Fat-to-Muscle Ratio, Significantly Correlates With Measured Insulin Resistance in Patients With Type 2 Diabetes Mellitus
por: Kurinami, Noboru, et al.
Publicado: (2021)

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2015)

Elevation of the renal threshold for glucose is associated with insulin resistance and higher glycated hemoglobin levels
por: Hieshima, Kunio, et al.
Publicado: (2020)

Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor
por: Sugiyama, Seigo, et al.
Publicado: (2020)

A Non-obese, Treatment-Naive Japanese Diabetic Patient With Elevated Insulin Clearance and Hyperglycemia Under Enhanced Insulin Sensitivity and Increased Insulin Secretion: Elevated Insulin Clearance as Type 2 Japanese Diabetes Mellitus (T2JDM)
por: Sugiyama, Seigo, et al.
Publicado: (2021)

Reduced Number of Remaining or Healthy Teeth in Patients with Type 2 Diabetes Mellitus: A Cross-sectional Study Assessed by Dentists or Dental Hygienists in Japan
por: Kurinami, Noboru, et al.
Publicado: (2023)

Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300 U mL(−1) and Glargine 100 U mL(−1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study
por: Jinnouchi, Hideaki, et al.
Publicado: (2015)

Possible renoprotective mechanisms of SGLT2 inhibitors
por: Nishiyama, Akira, et al.
Publicado: (2023)

Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats
por: Kojima, Naoki, et al.
Publicado: (2015)

Association between aldehyde dehydrogenase 2 polymorphisms and the incidence of diabetic retinopathy among Japanese subjects with type 2 diabetes mellitus
por: Morita, Kazunori, et al.
Publicado: (2013)

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus
por: Jinnouchi, Hideaki, et al.
Publicado: (2016)

Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
por: Panchapakesan, Usha, et al.
Publicado: (2013)

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
por: Giorgino, Francesco, et al.
Publicado: (2020)

Sex Differences in the Renal Function Decline of Patients with Type 2 Diabetes
por: Kajiwara, Ayami, et al.
Publicado: (2016)

Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis
por: Jinnouchi, Hideaki, et al.
Publicado: (2020)

Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease
por: Clemmer, John S., et al.
Publicado: (2023)

Low-Dose Aspirin Therapy in Patients With Type 2 Diabetes and Reduced Glomerular Filtration Rate: Subanalysis from the JPAD trial
por: Saito, Yoshihiko, et al.
Publicado: (2011)

Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study
por: Lin, Fang-Ju, et al.
Publicado: (2021)

Adaptive Response as a Potential Key Link Between SGLT2 Inhibition and Renoprotection
por: Sasako, Takayoshi, et al.
Publicado: (2021)

The Authors Reply:
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

An angiotensin II receptor blocker–calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone
por: Kim-Mitsuyama, Shokei, et al.
Publicado: (2013)

Combination Treatment of Rosuvastatin or Atorvastatin, with Regular Exercise Improves Arterial Wall Stiffness in Patients with Coronary Artery Disease
por: Toyama, Kensuke, et al.
Publicado: (2012)

Correction: Combination Treatment of Rosuvastatin or Atorvastatin, with Regular Exercise Improves Arterial Wall Stiffness in Patients with Coronary Artery Disease
por: Toyama, Kensuke, et al.
Publicado: (2013)

Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model
por: Kajiwara, Koichiro, et al.
Publicado: (2021)

Renoprotective potential of concomittant medications with SGLT2 inhibitors and renin-angiotensin system inhibitors in diabetic nephropathy without albuminuria: a retrospective cohort study
por: Ishibashi, Tatsuya, et al.
Publicado: (2023)

Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D
por: Blevins, Thomas, et al.
Publicado: (2020)

Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
por: Chanawong, Apichaya, et al.
Publicado: (2023)

Erratum. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016;39:139–148
por: Mita, Tomoya, et al.
Publicado: (2017)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
por: Esaki, Hiroki, et al.
Publicado: (2017)

Interactive effects of a common γ-glutamyltransferase 1 variant and low high-density lipoprotein-cholesterol on diabetic macro- and micro-angiopathy
por: Jinnouchi, Hideaki, et al.
Publicado: (2015)

Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study
por: Ishii, Hitoshi, et al.
Publicado: (2017)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes
por: Mizushige, Tomoko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_smq2vi2hrhcgl4r31mnhfs0fq2